The Antithrombin III pipeline drugs market research report outlays comprehensive information on the Antithrombin III targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Antithrombin III pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Hematological Disorders, Cardiovascular, and Infectious Disease which include the indications Antithrombin III Deficiency, Disseminated Intravascular Coagulation (DIC), Deep Vein Thrombosis (DVT), Venous Thromboembolism, and Sepsis. It also reviews key players involved in Antithrombin III targeted therapeutics development with respective active and dormant or discontinued products.
The Antithrombin III pipeline targets constitutes close to 12 molecules. Out of which, approximately 12 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical, and Discovery stages are 3, 1, 5, and 2 respectively.
Antithrombin III overview
Antithrombin III (SERPINC1 or AT-III) is a serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa, and XIa. Its inhibitory activity is greatly enhanced in the presence of heparin.
For a complete picture of Antithrombin III’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
